Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas

International Journal of Cancer

Volumn 103, Issue 3, 2003, Pages 352-359

  Kim, Sunghoon ^a   Kang, Junghee ^a   Hu, Wanqin ^a   Evers, B Mark ^a   Chung, Dai H ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Akt; Apoptosis; Geldanamycin; Neuroblastoma; Raf 1

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; CASPASE 3; CASPASE 9; CYTOCHROME C; DNA FRAGMENT; GELDANAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; RAF PROTEIN; RAF1 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CELL VIABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NERVE CELL; NEUROBLASTOMA; NICK END LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CASPASE 3; CASPASES; CYTOCHROME C GROUP; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; LACTAMS, MACROCYCLIC; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; NEUROBLASTOMA; POLY(ADP-RIBOSE) POLYMERASES; PRECIPITIN TESTS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; QUINONES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0037454761     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10820     Document Type: Article

References (54)

1. Ries LAG, Miller BA, Hankey BF. SEER cancer statistics review, 1973-1991. In: Ries LAG, Miller BA, Hankey BF, eds. Tables and Graphs, National Cancer Institute Bethesda, MD: NIH Pub. No. 94-2789, 1994.
2. Haase GM, Perez C, Atkinson JB. Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol 1999;16:91-104. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uid=9988866.
3. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 2001;61:4864-72. Available from http://cancerres.aacrjournals.org/cgi/content/full/61/12/4864 http://cancerres.aacrjournals.org/cgi/content/abstract/61/12/4864 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11406564.
4. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-9. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation &list_uids=10969767.
5. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, Brodeur GM. Resistance to tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001;61:1314-9. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=11245427.
6. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-35. Available from http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v6/n5/ full/nm0500_ 529.html http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/joumal/v6/n5/ abs/nm0500_529.html http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10802708.
7. Matthay KK. Neuroblastoma: Biology and therapy. Oncology (Huntingt) 1997;11:1857-66; discussion 69-72, 75. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed &dopt=Citation&list_uids=9436190.
8. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-62. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieveamp;db=Pub Medamp;dopt=Citationamp;list_uids=3306916.
9. Zhou XF, Rush R. Sympathetic neurons in neonatal rats require endogenous neurotrophin-3 for survival. J Neurosci 1995;15:6521-30. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=7472414.
10. Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, Ling LH, MacMahon SB, Shelton DL, Levinson AD. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994;76:1001-11. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=8137419.
11. Wyatt S, Pinon LG, Ernfors P, Davies AM. Sympathetic neuron survival and TrkA expression in NT3-deficient mouse embryos. EMBO J 1997;16:3115-23. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=9214629.
12. Francis N, Farinas I, Brennan C, Rivas-Plata K, Backus C, Reichardt L, Landis S. NT-3, like NGF, is required for survival of sympathetic neurons, but not their precursors. Dev Biol 1999;210:411-27. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10357900.
13. Orike N, Thrasivoulou C, Wrigley A, Cowen T. Differential regulation of survival and growth in adult sympathetic neurons: An in vitro study of neurotrophin responsiveness. J Neurobiol 2000;47:295-305.
14. Orike N, Middleton G, Borthwick E, Buchman V, Cowen T, Davies AM. Role of PI 3-kinase, Akt and Bcl-2-related proteins in sustaining the survival of neurotrophic factor-independent adult sympathetic neurons. J Cell Biol 2001;154:995-1005. Available from http://www.jcb.org/cgi/content/full/154/5/995 http://www.jcb.org/cgi/content/abstract/154/5/995 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=11524433.
15. Mazzoni IE, Said FA, Aloyz R, Miller FD, Kaplan D. Ras regulates sympathetic neuron survival by suppressing the p53-mediated cell death pathway. J Neurosci 1999;19:9716-27. Available from http://www.jneurosci.org/cgi/content/full/19/22/9716 http://www.jneurosci. org/cgi/content/abstract/19/22/9716 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10559381.
16. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996;19:463-89. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=8833451.
17. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000;10:147-54. Available from http://www.biomednet.com/library/fulltext/TCB.etd00275_09628924_ v0010i04_00001740 http://www.biomednet.com/library/abstract/TCB.etd00275_09628924_ v0010i04_00001740 http://www. ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed& dopt=Citation&list_uids=10740269.
18. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=8052307.
19. Xue L, Murray JH, Tolkovsky AM. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons. J Biol Chem 2000;275:8817-24. Available from http://www.jbc.org/cgi/content/full/275/12/8817 http://www.jbc. org/cgi/content/abstract/275/12/8817 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10722727.
20. Creedon DJ, Johnson EM, Lawrence JC. Mitogen-activated protein kinase-independent pathways mediate the effects of nerve growth factor and cAMP on neuronal survival. J Biol Chem 1996;271:20713-8. Available from http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8702822.
21. Virdee K, Xue L, Hemmings BA, Goemans C, Heumann R, Tolkovsky AM. Nerve growth factor-induced PKB/Akt activity is sustained by phosphoinositide 3-kinase dependent and independent signals in sympathetic neurons. Brain Res 1999;837:127-42. Available from http://www.elsevier.com:80/cgi-bin/cas/tree/store/bres/cas_sub/ browse/browse.cgi?year=1999&volume=837&issue=1-2&aid=15695 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10433995.
22. Klesse LJ, Parada LF. p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. J Neurosci 1998;18:10420-8. Available from http://www.jneurosci.org/cgi/content/full/18/24/10420 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=9852579.
23. Kurihara S, Hakuno F, Takahashi S. Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: The roles of MAP kinase pathway and PI 3-kinase pathway. Endocr J 2000;47:739-51. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=11228049.
24. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10759403.
25. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed& dopt=Citation&list_uids=7628050.
26. Uehara Y, Hori M, Takeuchi T, Umezawa H. Screening of agents which convert 'transformed morphology' of Rous sarcoma virusinfected rat kidney cells to 'normal morphology': Identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 1985;76:672-5. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=3930444.
27. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res 1994;54:2724-30. Available from http://www,ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=7909494.
28. Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni-Eda Y, Kurosawa M, Miyazaki T, Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 1992;80:1330-8. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=1515646.
29. Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R, Pratt WB. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 1993;268:21711-6. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=8408024.
30. Wartmann M, Davis RJ. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J Biol Chem 1994;269:6695-701. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation &list_uids=8120027.
31. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 2000;97:10832-7. Available from http://www.pnas.org/cgi/coutent/full/97/20/10832 http://www.pnas.org/cgi/content/abstract/97/20/10832 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10995457.
32. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 1997;239:655-9. Available from http://www.idealibrary.com/cgi-bin/links/artid/RC977527 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=9367823.
33. Ehlers RA, Kim S, Zhang Y, Ethridge RT, Murrilo C, Hellmich MR, Evans DB, Townsend CM, Jr., Evers BM. Gut peptide receptor expression in human pancreatic cancers. Ann Surg 2000;231:838-48. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10816627.
34. Evers BM, Zhou Z, Celano P, Li J. The neurotensin gene is a downstream target for Ras activation. J Clin Invest 1995;95:2822-30. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=7769122.
35. Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis. Cell 1997;91:443-6. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=9390553.
36. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998;281:1312-6. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=9721091.
37. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=9390557.
38. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& amp;db=PubMed&dopt=Citation&list_ids= 9721092.
39. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-l-Ras association. J Biol Chem 1995;270:24585-8. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& amp;db=PubMed&dopt=Citation&list_uids=7592678.
40. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995;31A:505-10. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& amp;db=PubMed&dopt=Citation&list_uids=7576954.
41. Cotterill SJ, Parker L, More L, Craft AW. Neuroblastoma: Changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry. Med Pediatr Oncol 2001;36:231-4. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& amp;db=PubMed&dopt=Citation&list_uids=11464892.
42. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino 17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9. Available from http://cancerres.aacrjournals. org/cgi/content/full/61/10/4003 http://cancerres.aacrjournals.org/cgi/content/abstract/61/10/4003 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& amp;db=PubMed&dopt=Citation&list_uids=11358818.
43. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61:1799-804. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& amp;db=PubMed&dopt=Citation&list_uids=11280726.
44. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6. Available from http://dx.doi.org/10.1021/jm980403y http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& amp;db=PubMed&dopt=Citation&lis_uids=9925731.
45. Scheibel T, Buchner J. The Hsp90 complex - A super-chaperone machine as a novel drug target. Biochem Pharmacol 1998;56:675-82. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=9751071.
46. Supino-Rosin L, Yoshimura A, Yarden Y, Elazar Z, Neumann D. Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins. J Biol Chem 2000;275:21850-5. Available from http://www.jbc.org/cgi/content/full/275/29/21850 http://www.jbc.org/cgi/content/ abstract/275/29/21850 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10806200.
47. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L, Liu ZG. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 2000;275:10519-26. Available from http://www.jbc.org/cgi/ content/full/275/14/10519 http://www.jbc.org/cgi/content/abstract/275/14/10519 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=10744744.
48. Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, Hartl FU. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 1996;93:14536-41. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed &dopt=Citation&list_uids=8962087.
49. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=10485711.
50. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pub Med&dopt=Citation&list_uids=9812896.
51. Lopez-Maderuelo MD, Fernandez-Renart M, Moratilla C, Renart J. Opposite effects of the Hsp90 inhibitor Geldanamycin: Induction of apoptosis in PC12, and differentiation in N2A cells. FEBS Lett 2001;490:23-7. Available from http://www.ncbi.nhn.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=11172804.
52. Schnur RC, Connan ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, Miller PE, O'Brien AT, et al. Inhibition of the oncogene product p 185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38:3806-12. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 7562911.
53. Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, Hait WN. Disruption of the EF-2 kinase/Hsp90 protein complex: A possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res 2001;61:4010-6. Available from http://cancerres.aacrjournals.org/cgi/content/full/61/10/4010 http://cancerres.aacrjournals.org/cgi/content/abstract/61/4010 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=11358819.
54. Donze O, Abbas-Terki T, Picard D. The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. EMBO J 2001;20:3771-80. Available from http://www.emboj. org/cgi/content/full/20/14/3771 http://www.emboj.org/cgi/content/abstract/20/14/3771 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=11447118.